• Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
Resistance to Targeted Therapies in Multiple Myeloma

Resistance to Targeted Therapies in Multiple Myeloma

Hardcover

Series: Resistance to Targeted Anti-Cancer Therapeutics, Book 22

Medical Reference

ISBN10: 3030734390
ISBN13: 9783030734398
Publisher: Springer Nature
Published: Jul 24 2021
Pages: 154
Weight: 0.93
Height: 0.44 Width: 6.14 Depth: 9.21
Language: English

Multiple Myeloma remains an incurable malignancy. As the disease progresses, it invariably becomes resistant to treatment and almost all patients develop refractory disease. There are multiple different types of targeted therapies and many of them are used in combination at different stages of disease. Targeted therapies that are approved to be used include Proteasome Inhibitors, Immunomodulatory Drugs and Monoclonal Antibodies. Second and third generations of these drugs are developed to overcome resistance and they have unique mechanism of actions. Targeted therapies that are undergoing clinical trials include CAR-T cells, bi-specific antibodies, vaccines, ubiquitin ligase inhibitors and BCL-2 inhibitors.

Also in

Medical Reference